[{"from": "human", "value": "What can you tell me about this molecule? [C][C][=C][C][C][C@@H1][Branch2][Ring1][C][C][=Branch1][C][=O][N][Ring1][#Branch1][C][=C][C][=C][C][=C][Ring1][=C][Ring1][=Branch1][C][C][=C][Branch1][=Branch1][N][C][=N][Ring1][Branch1][C]"}, {"from": "gpt", "value": "The molecule is an organic heterotricyclic compound that is 8,9-dihydropyrido[1,2-a]indol-6(7H)-one substituted by a (5-methyl-1H-imidazol-4-yl)methyl group at position 7R and a methyl group at position 10. It is a dual 5-HT3 and 5-HT4 receptors antagonist whose clinical development was terminated in phase II. It was being developed for the treatment of chemotherapy-induced emesis and irritable bowel syndrome. It has a role as an antiemetic and a serotonergic antagonist. It is a member of imidazoles and an organic heterotricyclic compound."}]